A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Exelixis

Criteria

For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email[email protected]. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.

Inclusion Criteria:

• Advanced or metastatic cancer (excluding cancer in the blood) or uncontrolled basal cell nevoid syndrome or sporadic basal cell carcinoma

• Primary or metastatic tumor site accessible for biopsy

• Ability to swallow capsules

• Subjects with histologically confirmed, advanced stage IIIB or stage IV non-small cell lung cancer (NSCLC) with a primary histology of squamous carcinoma who have received prior systemic therapy for advanced NSCLC will be enrolled in Part 3

Exclusion Criteria:

• Uncontrolled brain metastasis

• Significant cardiovascular disease

• Inadequate blood counts

• Inadequate liver, kidney or lung function

• Gastrointestinal disease within last 3 months

• Infection with Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C or exposure to attenuated active immunizations